RESUMO
The evolution in the knowledge of tuberculosis' physiopathology allowed not only a better understanding of the immunological factors involved in the disease process, but also the development of new laboratory tests, as well as the establishment of a histological classification that reflects the host's ability to contain the infectious agent. At the same time, the increasing bacilli resistance led to alterations in the basic tuberculosis treatment scheme in 2009. This article critically examines laboratory and histological investigations, treatment regimens for tuberculosis and possible adverse reactions to the most frequently used drugs.
Assuntos
Antituberculosos/uso terapêutico , Tuberculose Cutânea/tratamento farmacológico , Tuberculose Cutânea/patologia , Adolescente , Adulto , Idoso , Antibióticos Antituberculose/uso terapêutico , Criança , Feminino , Granuloma , Humanos , Isoniazida/uso terapêutico , Masculino , Mycobacterium tuberculosis , Necrose , Pirazinamida/uso terapêutico , Rifampina/uso terapêutico , Sensibilidade e EspecificidadeRESUMO
The evolution in the knowledge of tuberculosis' physiopathology allowed not only a better understanding of the immunological factors involved in the disease process, but also the development of new laboratory tests, as well as the establishment of a histological classification that reflects the host's ability to contain the infectious agent. At the same time, the increasing bacilli resistance led to alterations in the basic tuberculosis treatment scheme in 2009. This article critically examines laboratory and histological investigations, treatment regimens for tuberculosis and possible adverse reactions to the most frequently used drugs.
Assuntos
Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Antituberculosos/uso terapêutico , Tuberculose Cutânea/tratamento farmacológico , Tuberculose Cutânea/patologia , Antibióticos Antituberculose/uso terapêutico , Granuloma , Isoniazida/uso terapêutico , Mycobacterium tuberculosis , Necrose , Pirazinamida/uso terapêutico , Rifampina/uso terapêutico , Sensibilidade e EspecificidadeRESUMO
Cutaneous tuberculosis (CTB) is the result of a chronic infection by Mycobacterium tuberculosis, M. ovis and occasionally by the Calmette-Guerin bacillus. The clinical manifestations are variable and depend on the interaction of several factors including the site of infection and the host's immunity. This article revises the current knowledge about this disease's physiopathology and immunology as well as detailing the possible clinical presentations.
Assuntos
Tuberculose Cutânea/epidemiologia , Tuberculose Cutânea/patologia , Brasil/epidemiologia , Progressão da Doença , Humanos , Mycobacterium tuberculosis , Pele/patologia , Tuberculose Cutânea/microbiologiaRESUMO
Cutaneous tuberculosis (CTB) is the result of a chronic infection by Mycobacterium tuberculosis, M. ovis and occasionally by the Calmette-Guerin bacillus. The clinical manifestations are variable and depend on the interaction of several factors including the site of infection and the host's immunity. This article revises the current knowledge about this disease's physiopathology and immunology as well as detailing the possible clinical presentations.
Assuntos
Humanos , Tuberculose Cutânea/epidemiologia , Tuberculose Cutânea/patologia , Brasil/epidemiologia , Progressão da Doença , Mycobacterium tuberculosis , Pele/patologia , Tuberculose Cutânea/microbiologiaRESUMO
Psoriasis is a chronic inflammatory disease affecting the skin and occasionally the joints. The biological agents have been engineered to target a specific step in the inflammatory cascade that leads to psoriasis, including tumor necrosis factor, which has a central role in the host defense against Mycobacterium tuberculosis. This is a case report about a psoriatic patient who presented splenic tuberculosis during treatment with infliximab.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Fármacos Dermatológicos/efeitos adversos , Psoríase/tratamento farmacológico , Tuberculose Esplênica/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Humanos , Infliximab , MasculinoRESUMO
A psoríase é doença crônica que afeta a pele e, eventualmente, as articulações. A terapia biológica age bloqueando citocinas inflamatórias implicadas na patogênese da doença, dentre elas o fator de necrose tumoral alfa. Este também tem papel na defesa do hospedeiro contra o Mycobacterium tuberculosis. Relata-se um caso de psoríase com boa resposta ao infliximabe, porém com desenvolvimento de tuberculose esplênica durante o tratamento.
Psoriasis is a chronic inflammatory disease affecting the skin and occasionally the joints. The biological agents have been engineered to target a specific step in the inflammatory cascade that leads to psoriasis, including tumor necrosis factor, which has a central role in the host defense against Mycobacterium tuberculosis. This is a case report about a psoriatic patient who presented splenic tuberculosis during treatment with infliximab.
